Where can I find BIOVF's financial statements?

Swedish Orphan Biovitrum AB (publ) (BIOVF)'s full income statement, balance sheet, and cash flow statement are on this page in 10-K-style line-item format. Switch between the three statements via the pill toggle above the table.

How much history is available for BIOVF?

Swedish Orphan Biovitrum AB (publ) (BIOVF) statements are available back to its earliest filed 10-K — typically 10+ years of annual data and 40 quarters of quarterly data. Free-tier users see 5 years and 8 quarters; full history unlocks with a Pro account.

How often does BIOVF update its statements?

Swedish Orphan Biovitrum AB (publ) files a 10-K annually (full audited year-end statements) and 10-Q reports quarterly (unaudited interim statements). New filings are typically parsed and reflected on this page within 48 hours of SEC submission.

BIOVF

Swedish Orphan Biovitrum AB (publ)

OTC·Drug Manufacturers, Specialty & Generic · Healthcare

$49.03$0.00+0.00%

Market cap$17.03B·Market closed·Jul 20 8:00 PM UTC

SEK · values shown as reported

Line item	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Revenue	kr 15.48B+1.4%	kr 18.79B+21.4%	kr 22.12B+17.7%	kr 26.03B+17.6%	kr 28.17B+8.2%
Cost of revenue	kr 3.48B+8.0%	kr 4.78B+37.1%	kr 5.00B+4.6%	kr 5.79B+15.8%	kr 15.88B+174.5%
Gross profit	kr 11.99B−0.4%	kr 14.01B+16.9%	kr 17.13B+22.2%	kr 20.24B+18.2%	kr 12.29B−39.3%
Research & development	kr 1.99B+25.1%	kr 2.35B+18.1%	kr 2.80B+18.8%	kr 3.54B+26.5%	kr 3.24B−8.4%
General & administrative	kr 6.29B+5.2%	kr 7.85B+24.7%	kr 10.16B+29.5%	kr 7.55B−25.7%	kr 11.14B+47.5%
Selling & marketing	—	—	—	kr 3.53B	—
SG&A (combined)	kr 6.29B+5.2%	kr 7.85B+24.7%	kr 10.16B+29.5%	kr 11.09B+9.1%	kr 11.14B+0.5%
Other operating expenses	−kr 30.00M−1,400.0%	−kr 32.00M−6.7%	kr 105.00M+428.1%	−kr 6.00M−105.7%	−kr 10.12B−168,626.1%
Total operating expenses	kr 8.26B+9.0%	kr 10.17B+23.1%	kr 13.06B+28.4%	kr 14.62B+11.9%	kr 4.26B−70.8%
Operating income	kr 3.73B−22.5%	kr 3.81B+2.1%	kr 4.07B+6.6%	kr 5.63B+38.3%	kr 8.03B+42.7%
Interest income	—	kr 5.00M	kr 27.00M+440.0%	kr 32.00M+18.5%	—
Interest expense	kr 419.00M−7.7%	kr 458.00M+9.3%	kr 1.11B+142.6%	kr 1.24B+11.5%	kr 828.92M−33.1%
Other income / (expense), net	−kr 384.00M+36.1%	−kr 492.00M−28.1%	−kr 1.11B−126.0%	−kr 1.22B−9.5%	−kr 7.99B−556.3%
Income before tax	kr 3.35B−20.6%	kr 3.32B−0.8%	kr 2.95B−11.1%	kr 4.41B+49.2%	kr 33.91M−99.2%
Income tax expense	kr 670.00M−31.1%	kr 683.00M+1.9%	kr 546.00M−20.1%	kr 528.00M−3.3%	−kr 440.89M−183.5%
Net income	kr 2.68B−17.4%	kr 2.64B−1.5%	kr 2.41B−8.7%	kr 3.89B+61.3%	kr 476.80M−87.7%

EPS (basic)	kr 8.67−17.6%	kr 8.52−1.7%	kr 7.39−13.3%	kr 11.37+53.9%	kr 1.39−87.8%
EPS (diluted)	kr 8.62−17.2%	kr 8.44−2.1%	kr 7.39−12.4%	kr 11.24+52.1%	kr 1.38−87.7%
Weighted avg shares (basic)	308,898,546	309,477,633	325,981,055	341,727,000	344,299,173
Weighted avg shares (diluted)	310,728,940	312,455,244	325,967,648	345,562,000	347,608,339

Depreciation & amortization	kr 2.00B−1.2%	kr 2.27B+13.7%	kr 3.17B+39.4%	kr 3.68B+16.1%	kr 10.07B+173.7%
EBITDA	kr 5.71B−14.7%	kr 6.05B+5.9%	kr 7.23B+19.6%	kr 9.33B+28.9%	kr 10.94B+17.3%

Frequently Asked Questions About BIOVF

Where can I find BIOVF's financial statements?: Swedish Orphan Biovitrum AB (publ) (BIOVF)'s full income statement, balance sheet, and cash flow statement are on this page in 10-K-style line-item format. Switch between the three statements via the pill toggle above the table.
How much history is available for BIOVF?: Swedish Orphan Biovitrum AB (publ) (BIOVF) statements are available back to its earliest filed 10-K — typically 10+ years of annual data and 40 quarters of quarterly data. Free-tier users see 5 years and 8 quarters; full history unlocks with a Pro account.
How often does BIOVF update its statements?: Swedish Orphan Biovitrum AB (publ) files a 10-K annually (full audited year-end statements) and 10-Q reports quarterly (unaudited interim statements). New filings are typically parsed and reflected on this page within 48 hours of SEC submission.

Line item

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Trend

Revenue

kr 15.48B+1.4%

kr 18.79B+21.4%

kr 22.12B+17.7%

kr 26.03B+17.6%

kr 28.17B+8.2%

Cost of revenue

kr 3.48B+8.0%

kr 4.78B+37.1%

kr 5.00B+4.6%

kr 5.79B+15.8%

kr 15.88B+174.5%

Gross profit

kr 11.99B−0.4%

kr 14.01B+16.9%

kr 17.13B+22.2%

kr 20.24B+18.2%

kr 12.29B−39.3%

Research & development

kr 1.99B+25.1%

kr 2.35B+18.1%

kr 2.80B+18.8%

kr 3.54B+26.5%

kr 3.24B−8.4%

General & administrative

kr 6.29B+5.2%

kr 7.85B+24.7%

kr 10.16B+29.5%

kr 7.55B−25.7%

kr 11.14B+47.5%

Selling & marketing

—

kr 3.53B

—

SG&A (combined)

kr 6.29B+5.2%

kr 7.85B+24.7%

kr 10.16B+29.5%

kr 11.09B+9.1%

kr 11.14B+0.5%

Other operating expenses

−kr 30.00M−1,400.0%

−kr 32.00M−6.7%

kr 105.00M+428.1%

−kr 6.00M−105.7%

−kr 10.12B−168,626.1%

Total operating expenses

kr 8.26B+9.0%

kr 10.17B+23.1%

kr 13.06B+28.4%

kr 14.62B+11.9%

kr 4.26B−70.8%

Operating income

kr 3.73B−22.5%

kr 3.81B+2.1%

kr 4.07B+6.6%

kr 5.63B+38.3%

kr 8.03B+42.7%

Interest income

—

kr 5.00M

kr 27.00M+440.0%

kr 32.00M+18.5%

—

Interest expense

kr 419.00M−7.7%

kr 458.00M+9.3%

kr 1.11B+142.6%

kr 1.24B+11.5%

kr 828.92M−33.1%

Other income / (expense), net

−kr 384.00M+36.1%

−kr 492.00M−28.1%

−kr 1.11B−126.0%

−kr 1.22B−9.5%

−kr 7.99B−556.3%

Income before tax

kr 3.35B−20.6%

kr 3.32B−0.8%

kr 2.95B−11.1%

kr 4.41B+49.2%

kr 33.91M−99.2%

Income tax expense

kr 670.00M−31.1%

kr 683.00M+1.9%

kr 546.00M−20.1%

kr 528.00M−3.3%

−kr 440.89M−183.5%

Net income

kr 2.68B−17.4%

kr 2.64B−1.5%

kr 2.41B−8.7%

kr 3.89B+61.3%

kr 476.80M−87.7%

EPS (basic)

kr 8.67−17.6%

kr 8.52−1.7%

kr 7.39−13.3%

kr 11.37+53.9%

kr 1.39−87.8%

EPS (diluted)

kr 8.62−17.2%

kr 8.44−2.1%

kr 7.39−12.4%

kr 11.24+52.1%

kr 1.38−87.7%

Weighted avg shares (basic)

308,898,546

309,477,633

325,981,055

341,727,000

344,299,173

Weighted avg shares (diluted)

310,728,940

312,455,244

325,967,648

345,562,000

347,608,339

Depreciation & amortization

kr 2.00B−1.2%

kr 2.27B+13.7%

kr 3.17B+39.4%

kr 3.68B+16.1%

kr 10.07B+173.7%

EBITDA

kr 5.71B−14.7%

kr 6.05B+5.9%

kr 7.23B+19.6%

kr 9.33B+28.9%

kr 10.94B+17.3%